Skip to main content

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
Cancel
×
×
Home
  • Home
Chapter
  • Print publication year: 2009
  • Online publication date: December 2009

Chapter 24 - Coronary heart disease

from Section 6 - Common medical problems
Export citation
Summary
This chapter discusses the diagnosis, evaluation, staging and prognosis and treatment of postmenopausal bleeding and endometrial cancer. The primary symptom of endometrial cancer (ECa) is postmenopausal bleeding (PMB). A physical examination of PMB should look for vaginal and cervical abnormalities, polyps, masses, uterine size and symmetry, or ovarian masses. ECa (cancer of the body or corpus of the uterus) is the fourth most common malignancy in women in the USA, and seventh most common cause of cancer deaths in women. Prognostic factors are related to age, race, endocrine status, histological cell type, tumor grade, depth of myometrial invasion, extension beyond the uterus, adnexal metastases, and extrauterine and peritoneal spread. PMB has a variety of causes, one of which is endometrial cancer. Endometrial cancer is usually discovered at an early stage, is curable, and is usually a disease of postmenopausal women.

Keywords:

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Handbook of Women's Health
  • Online ISBN: 9780511642111
  • Book DOI: https://doi.org/10.1017/CBO9780511642111
Please enter your name
Please enter a valid email address
Who would you like to send this to *

CAPTCHA *

Skip to the audio challenge
×

References

1.Heart disease and stroke statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113(6), e85–151.
2. WingoP. A., CalleE. E., McTiernanA. How does breast cancer mortality compare with that of other cancers and cardiovascular diseases at different ages in US women?J Womens Health Gend Based Med 2000; 9, 999–1000.
3. MoscaL., AppelL. J., et al. Evidence-based guidelines for cardiovascular disease prevention in women; AHA scientific statement, consensus panel statement. Circulation 2004; 99, 2480–2484.
4. DawberT. R., KannelW. B., RevotskieN., StokesJ. I., KaganA., GordonT. Some factors associated with the development of coronary heart disease; six years' follow-up experience in the Framingham Study. Am J Public Health 1959; 49, 1349–1356.
5. WilsonP. W. F., D'AgostinoR. B., LevyD., BelangerA. M., SilbershatzH., KannelW. B.Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97, 1837–1847.
6. Rich-EdwardsJ. W., MansonJ. E., HennekensC. H., BuringJ. E.The primary prevention of coronary heart disease in women. N Engl J Med 1995; 332, 1758–1766.
7. BushT. L.The epidemiology of cardiovascular disease in postmenopausal women. Ann NY Acad Sci 1990; 592, 263–271.
8. MoscaL., MansonJ. E., SutherlandS. E., et al. Cardiovascular disease in women. A statement for healthcare professionals from the American Heart Association. Circulation 1997; 96, 2468–2482.
9. NCEP. Summary of Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel II). J Am Med Assoc 1993; 269, 3015–3023.
10. WinkelbyM. A., KraemerH. C., AhnD. K., VaradyA. N.Ethnic and socioeconomic differences in cardiovascular disease risk factors. J Am Med Assoc 1998; 280, 356–362.
11. Joint National Committee on the Detection, Evaluation, and Treatment of Blood Pressure. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42, 1206.
12. GueyffierF., BoutitieF., BoisselJ. P., et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomized controlled trials. Ann Intern Med 1997; 126, 761–767.
13. WalshJ. M. E., PignoneM. Drug treatment of hyperlipidemia in women. J Am Med Assoc 2004; 291, 2243–2252.
14. FordE. S., et al. Serum cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Survey, 1999 to 2000. Circulation 2003; 107, 2185–2189.
15. ManolioT. A., PearsonT. A., WengberN. K., et al. Cholesterol and heart disease in older persons and women. Ann Epidemiol 1992; 2, 161–176.
16. BassK. M., NewschafferC. H., KlagM. J., BushT. L.Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993; 153, 2209–2216.
17. JacobsD. R. Jr., MebanI. L., BangdiwalaS. I., CriquiM. H., TyrolerH. A.High-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinic Prevalence Study. Am J Epidemiol 1990; 131, 32–47.
18. HokansonJ. E., AustinM. A.Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3(2), 213–219.
19. AustinM. A., HokansonJ. E., EdwardsK. L.Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81(4A), 7B–12B.
20. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,538 high-risk individuals: a randomized placebo controlled trial. Lancet 2002; 360, 7–22.
21. NCEP. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel III). J Am Med Assoc 2001; 285, 2486–2497.
22. Institute for Clinical Systems Improvement (ICSI). Lipid Management in Adults, Bloomington, MN: ICSI, 2006.
23. WillettW. C., GreenA., StampferM. J., et al. Relative and absolute excess risk of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987; 317, 1303–1309.
24.National Health Interview Survey (NHIS), January–June 2006. Bethesda, MD: National Center for Health Statistics.
25. HansenE. F., AndersenL. T., Von EybenF. E.Cigarette smoking and age at first acute myocardial infarction, and influence of gender and extent of smoking. Am J Cardiol 1993; 71, 1439–1442.
26. RosenbergL., PalmerJ. R., ShapiroS. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med 1990; 322, 213–217.
27. WilsonK., GibsonN., WillanA., CookD. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000; 160(7), 939–944.
28. GeissL. S., HermanW. H., SmithP. J.Mortality in non-insulin-dependent diabetes. In Diabetes in America, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, 1995, pp. 249–250.
29. MansonJ. E., SpelsbergA. Risk modification in the diabetic patient. In MansonJ. E., RidkerP. M., GazianoJ. M., HennekensC. H., eds., Prevention of Myocardial Infarction, New York: Oxford University Press, 1996, pp. 241–273.
30. GuK., et al. Diabetes and decline in heart disease mortality in US adults. J Am Med Assoc 1999; 281, 1291–1297.
31. Centers for Disease Control and Prevention. The Third National Health and Nutrition Examination Survey (NHANES III 1988–94) Reference Manuals and Reports. Bethesda, MD: National Center for Health Statistics, 1996.
32. HuntK. J., ResendezR. G., WilliamsK., et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110, 1251–1257.
33. KushiL. H., FeeR. M., FolsomA. R., MinkP. J., AndersonK. E., SellersT. A.Physical activity and mortality in postmenopausal women. J Am Med Assoc 1997; 277, 1287–1292.
34. StampferM. J., HuF. B., MansonJ. E., RimmE. B., WillettW. C.Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000; 343, 16–22.
35. National Center for Health Statistics, http://www.cdc.gov/nchs/products/pubs/pubd/hestats/3and4/sedentary.htm, accessed 12/06.
36. BlairS. N., KohlH. W. III, PaffenbargerR. S. Jr., ClarkD. G., CooperK. H., GibbonsL. W.Physical fitness and all-cause mortality; a prospective study of healthy men and women. J Am Med Assoc 1989; 262, 2395–2401.
37. ColditzG. A., CoakleyE. Weight, weight gain, activity, and major illnesses: the Nurses' Health Study. Int J Sports Med 1997; 18(suppl 3), S162–S170.
38. KuczmarskiR. J., FlegalK. M., CampbellS. M., JohnsonC. L.Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960 to 1991. J Am Med Assoc 1994; 272, 205–211.
39. MansonJ. E., StampferM. J., ColditzG. A., et al. A prospective study of obesity and the risk of coronary heart disease in women. N Engl J Med 1990; 322, 882–889.
40. KaplanN. M.The deadly quartet: upper body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149, 1514–1520.
41. BjorntorpP. Regional patterns of fat distribution. Ann Intern Med 1985; 103, 994–995.
42. GleimG. W.Exercise is not an effective weight loss modality in women. J Am Coll Nutr 1993; 12, 363–367.
43. GrodsteinF., MansonJ. E., ColditzG. A., WillettW. C., SpeizerF. E., StampferJ. M.A prospective, observational study on hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133, 933–941.
44Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Am Med Assoc 1995; 273, 199–208.
45. HullyS., GradyD., BushT., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998; 280, 605–613.
46.Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288, 321–333.
47. SalpeterS. R., WalshJ. E., GreyberE., SalpeterE. E.Coronary heart disease events associated with hormone therapy in younger and older women, a meta-analysis. J Gen Intern Med 2006; 21(4), 363–366.
48. MoscaL., AppelL. J., BenjaminE. J., et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004; 109, 672–693.
49. ClearfieldM. Coronary heart disease risk reduction in postmenopausal women: the role of statin therapy and hormone replacement therapy. Prev Cardiol 2004; 7, 131–136.
50. LiaoJ. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 2002; 86, 5–18.
51. JonesP. H., DavidsonM. H., SteinE. A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR) trial. Am J Cardiol 2003; 92, 152–160.
52. MoscaL., BankaC. L., BenjaminE. J., et al., for the American Heart Association Expert Panel/Writing Group. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. American Heart Association website, available at http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.
53. The Steering Committee of the Physicians' Health Study Research Group. Final report from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321, 129–135.
54. RidkerP. M., CookM. R., LeeI.-M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352(13), 1293–1304.
55. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308, 81–106.
56. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2, 349.
57. HarringtonR. A., BeckerR. C., EzekowitzM., et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126, 513S.
58. BraunwaldE., AntmanE., BeasleyJ., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. Available at www.acc.org/qualityandscience/clinical/statements.htm, accessed 12/23/06.
59. HaydenM., PignoneM., PhillipsC., MulrowC. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 136, 161–172.
60. KrumholzH. M., PhilbinD. M. Jr., WangY., et al. Trends in the quality of care for Medicare beneficiaries admitted to the hospital with unstable angina. J Am Coll Cardiol 1998; 31, 957.
61. StaffordR. S.Aspirin use is low among United States outpatients with coronary artery disease. Circulation 2000; 101, 1097.
62. StampferM. J., HennekensC. H., MansonJ. E., et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328, 1444.
63. de Gaetano, G.Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357, 89.
64MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360, 23.
65. McCarthyB. C., BeshanskyJ. R., D'AgostinoR. B., SelkerH. P.Missed diagnoses of acute myocardial infarction in the emergency department: results from a multicenter study. Ann Emerg Med 1993; 22, 579–582.
66. PopeJ. H., AufderheideT. P., RuthazerR., WoolardR. H., FeldmanJ. A., BeshankyJ. R., et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000; 342, 1163–1170.
67. GoldbergR., GoffD., CooperL., LuepkerR., ZapkaH., BittnerV., et al. Age and sex differences in presentation of symptoms among patients with acute coronary disease: the REACT trial. Coron Artery Dis 2000; 11, 399–407.
68. MilnerK. A., FunkM., RichardsS., WilmesR. M., VaccarinoV., KrumholzH. M.Gender differences in symptom presentation association with coronary heart disease. Am J Cardiol 1999: 84, 396–399.
69. GoldmanL., CookE. F., BrandD. A., LeeT. H., RouanG. W., WeisbergM. C., et al. A computer protocol to predict myocardial infarction in emergency department patients with chest pain. N Engl J Med 1988; 318, 797–803.
70. SullivanA. K., HoldrightD. R., WrightC. A., et al. Chest pain in women: clinical, investigative, and prognostic features. Br Med J 1994; 308, 883–886.
71. SheiferS. E., CanosM. R., WeinfurtK. P., AroraU. K., MendelsohnF. O., GershB. J., WeissmanN. J.Sex differences in coronary artery size assessed by intravascular ultrasound. Am Heart J 2000; 139, 649–653.
72. KudenchukP. J., MaynardC., MartinJ. S., WirkusM., WeaverW. D.Comparison of presentation, treatment, and outcome of acute myocardial infarction in men versus women (the Myocardial Infarction Triage and Intervention Registry). Am J Cardiol 1996; 78, 9–14.
73. PepineC. J.Angina pectoris in a contemporary population: characteristcs and therapeutic implications. TIDES Investigators. Cardiovasc Drugs Ther 1998; 12(Supp 3), 211–216.
74. LegatoM. J.Gender-specific physiology: how real is it? How important is it?Int J fertil 1997; 42(1), 19–29.
75. LightK. C., HerbstM. C., BragdonE. E., HinderliterA. L., KochG. G., DavisM. R., et al. Depression and type A behavior pattern in patients with coronary artery disease: relationships to painful versus silent myocardial ischemia and B-endorphin responses during exercise. Psychosom Med 1991; 53, 669–683.
76. CarneyR. M., BlumenthalJ. A., SteinP. K., WatkinsL., CatellierD., BerkmanL. F., et al. Depression, heart rate variability, and acute myocardial infarction. Circulation 2001; 104, 2024–2028.
77. AyanianJ. Z., EpsteinA. M.Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med 1991; 325(4), 221–225.
78. RogerV. L., FarkouhM. E., WestonS. A., ReederG. S., JacobsenS. J., ZinsmeisterA. R., et al. Sex differences in evaluation and outcome of unstable angina. J Am Med Assoc 2000; 283(5), 646–652.
79. MehtaR. H., MontoyeC. K., FaulJ., et al. Enhancing quality of care for acute myocardial infarction: shifting the focus of improvement form key indicators to process of care and tool use. J Am Coll Cardiol 2004; 43, 2166–2173.
80. MehtaR. H., MontoyeC. K., GalloglyM., et al. Improving quality of care for acute myocardial infarction: the Guidelines Applied in Practice (GAP) initiative. J Am Med Assoc 2002; 287, 1269–1276.
81. RyanT. J., AntmanE. M., BrooksN. H., et al. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999; 100, 1016–1030.
82. ACC/AHA 2002 Guideline Update for Exercise Testing: a Report of the American College of Cardiology/AHA Task Force on Practice Guidelines. www.americanheart.org.
83. ChaitmanB. R., BourassaM. G., DavisK., et al. Angiographic prevalence of high risk coronary artery disease in patient subsets (CASS). Circulation 1981; 64, 360–367.
84. MillerD. D.Noninvasive diagnosis of CAD in women. J Myocard Ischem 1995; 7, 263–268.
85. SchlantR. C., BlomqvistC. G., BrandenburgR. O., et al. Guidelines for exercise testing: a report of the Joint American College of Cardiology/American Heart Association Task Force on Assessment of Cardiovascular Procedures (Subcommittee on Exercise Testing). Circulation 1986; 74(3), 653–667A.
86. ClarkP. I., GlasserS. P., LymanG. H., et al. Relation of results of exercise stress tests in young women to phases of the menstrual cycle. Am J Cardiol 1988; 61(1), 197–199.
87. HungJ., ChaitmanB. R., LamJ., et al. Noninvasive diagnostic test choices for the evaluation of coronary artery disease in women: a multivariate comparison of cardiac fluoroscopy, exercise electrocardiography and exercise thallium myocardial perfusion scintigraphy. J Am Coll Cardiol 1984; 4(1), 8–16.
88. MarwickT. H., AndersonT., WilliamsM. J., et al. Exercise echocardiography is an accurate and cost-effective technique for detection of coronary artery disease in women. J Am Coll Cardiol 1995; 26, 335–341.
89. WeinerD. A., RyanT. J., ParsonsL., et al. Long-term prognostic value of exercise testing in men and women from the Coronary Artery Surgery Study (CASS) registry. Am J Cardiol 1995; 75(14), 865–870.
90. PrattC. M., FrancisJ. M., DivineG. W., YoungJ. B.Exercise testing in women with chest pain. Are there additional exerice characteristics that predict true positive test results?Chest 1989; 95, 139–144.
91. MoraS., RedbergR. F., CuiY., WhitemanM. K., FlawsJ. A., SharrettA. R., BlumenthalR. S.Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. J Am Med Assoc 2003; 290, 1600–1607.
92. KaskiJ. C., RosanoG. M. C., CollinsP., NihoyannopoulosP., MaseriA., Poole-WilsonP. A.Cardiac syndrome X: clinical characteristics and left ventricular function. J Am Coll Cardiol 1995; 25, 807–814.
93. VaccarinoV., ParsonsL., EveryN. R., BarronH. V., KrumholzH. M.Sex-based differences in early mortality after myocardial infarction. N Engl J Med 1999; 341, 217–225.
94. ChandraN. C., RogersW. J., Tiefenbrunn, A. J., et al. for the National Registry of Myocardial Infarction (NRMI) Investigators. High MI mortality in women: gender or age?JACC 1993; 21(Suppl A), 347A.
95. WeaverW. D., WhiteH. D., WilcoxR. G., et al. Comparisons of characteristics and outcomes among women and men with acute MI treated with thrombolytic therapy. J Am Med Assoc 1996; 275, 777–782.
96. HochmanJ. S., TamisJ. E., ThompsonT. D., et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. N Engl J Med 1999; 341, 226–232.
97. O'ConnorG. T., MortonJ. R., DiehlM. J., et al. Differences between men and women in hospital mortality associated with coronary artery bypass graft surgery. Circulation 1993; 88, 2104–2110.
98. VaccarinoV., AbramsonJ. L., VeledarE., et al. Sex differences in hospital mortality after coronary artery bypass surgery: evidence for a higher mortality in younger women. Circulation 2002; 105, 1176–1181.
99. JacobsA. K.Coronary revascularization in women in 2003: sex revisited. Circulation 2003; 107, 375.
100. JacobsA. K., KelseyS. F., BrooksM. M., et al. Better outcome for women compared with men undergoing coronary revascularization a report from the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1998; 98, 1279–1285.
101. JacobsA. K., JohnstonJ. M., HavilandA., et al. Improved outcomes for women undergoing contemporary percutaneous coronary intervention: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 2002; 39, 1606–1614.
102. ChoL., TopolE. J., BalogC., et al. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. J Am Coll Cardiol 2000; 36, 381–386.
103. HogueC. W. Jr., BarzilaiB., PieperK. S., et al. Sex differences in neurological outcomes and mortality after cardiac surgery: a Society of Thoracic Surgery National Database report. Circulation 2001; 103, 2133–2137.
104. HerlitzJ., Brandrup-WognsenG., KarlsonB. W., et al. Mortality, risk indicators of death, mode of death and symptoms of angina pectoris during 5 years after coronary artery bypass grafting in men and women. J Intern Med 2000; 247, 500–506.
105. MoriceM.-C., SerruysP. W., SousaJ. E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346, 1173–780.
106. MosesJ. W., LeonM. B., PopmaJ. J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349, 1315–1323.
107. SousaJ. E., CostaM. A., AbizaidA., et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001; 103, 192–195.
Cancel
Confirm
×